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supplementation over 12 weeks had no significant effect on 
VO2 max (P = 0.375), vertical jump height (P = 0.797), 
left and right handgrip strength (P = 0.146 and P = 0.266, 
respectively), forced vital capacity (P = 0.573) or forced 
expiratory volume at 1 s (P = 0.665), after adjusting for 
confounders. The high prevalence of vitamin D inadequacy 
observed in this cohort of collegiate Gaelic footballers sup-
ports the need for vitamin D supplementation during win-
tertime to avoid being at risk of poor bone health.
Conclusions Twelve-week daily supplementation with 
3000 IU (75 µg) vitamin D3 successfully resolved defi-
ciency but did not have any significant effect on VO2 max, 
skeletal muscle or lung function.
Keywords Vitamin D · VO2 max · Athletes · Randomised 
controlled trial · Football
Introduction
Vitamin D insufficiency and deficiency can be defined as 
a total serum 25-hydroxyvitamin D (25[OH]D) concentra-
tion below 50 and 30 nmol/L, respectively [1]. Such low 
total 25(OH)D concentrations are widespread, and a grow-
ing number of studies around the globe have identified this 
health concern in athletes [2–5]. Vitamin D and its metabo-
lites are renowned for their pivotal role in establishing mus-
culoskeletal health during childhood and adolescence and 
in hindering the development of skeletal pathology [6]. In 
addition, a growing body of evidence has demonstrated the 
importance of vitamin D beyond bone health on immune, 
cardiopulmonary and skeletal muscle function [7].
Biologically inactive total 25(OH)D is comprised 
of 25(OH)D2 and 25(OH)D3, compounds that are both 
formed following hepatic hydroxylation of vitamin D2 
Abstract 
Purpose  Vitamin D inadequacy is a global health con-
cern in athletes as well as the general population. Whilst 
the role of vitamin D in skeletal health is well defined, 
there remains uncertainty over whether vitamin D supple-
mentation has an added benefit beyond bone health.
Methods This randomised placebo-controlled trial in 
healthy male and female Gaelic footballers (n = 42) inves-
tigated the effect of vitamin D3 supplementation [3000 IU 
(75 µg) daily for 12 weeks, via an oral spray solution] 
on VO2 max which was the primary outcome measure. 
Secondary outcomes included skeletal muscle and lung 
function.
Results Supplementation significantly increased total 
25-hydroxyvitamin D concentrations compared to the 
placebo group (mean ± SD change from baseline, 
36.31 ± 32.34 vs. 6.11 ± 23.93 nmol/L, respectively; 
P = 0.006). At baseline, 50 and 22 % of footballers pre-
sented with vitamin D insufficiency (31–49 nmol/L) and 
deficiency (<30 nmol/L), respectively. Total 25-hydroxyvi-
tamin D concentration did not significantly correlate with 
any measure of physical performance. Analysis of covari-
ance (ANCOVA) models demonstrated that vitamin D 
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(ergocalciferol) and vitamin D3 (cholecalciferol) [8]. Ergo-
calciferol is derived from fungi exposed to ultraviolet B 
radiation (UVB) [9]. In humans, cholecalciferol is pro-
duced following exposure of cutaneous cells to UVB at a 
wavelength of 290–315 nm and is also present in oily fish, 
eggs and liver [10]. Calcitriol (1,25-dihydroxyvitamin D 
(1,25[OH]2D) is formed subsequent to renal hydroxyla-
tion of 25(OH)D, and it is this hormonally active com-
pound that has been implicated in numerous processes 
involving the immune, cardiovascular and respiratory sys-
tems [11]. Binding of 1,25[OH]2D to its nuclear receptor 
(VDR) results in the formation of a VDR-retinoid X recep-
tor (RXR) heterodimer that enables 1,25(OH)2D to act as 
a transcriptional regulator through binding to response ele-
ments located in the DNA of vitamin D target tissues [12].
In observational studies of both athletes and non-ath-
letes, total 25(OH)D concentration has been positively 
associated with measures of aerobic fitness although find-
ings have not been consistent [13–19]. One such measure 
is VO2 max, the maximal volume of oxygen utilised, per 
minute, during exhaustive exercise, which is considered 
the gold-standard measure of aerobic fitness and is related 
to distance covered in field games [20]. VO2 max is deter-
mined by a range of overriding factors including cardiac 
output, oxygen transit time and oxygen saturation [21].
A major limitation of existing observational research in 
this area is its inability to determine causality, and there-
fore, it is not known whether total 25(OH)D concentra-
tion is a cause of increased VO2 max or simply a result 
of reverse causation, perhaps owing to increased outdoor 
training time [22]. Despite the paucity of randomised con-
trolled trials investigating this relationship, there is sig-
nificant evidence of mechanisms by which vitamin D may 
influence factors that determine VO2 max [23–25]. One 
such mechanism is the ability of 1,25(OH)2D to suppress 
mRNA expression of hepcidin, the negative regulator of 
systemic iron concentration, an action which has been asso-
ciated with increased expression of ferroportin in hepato-
cytes and monocytes [24]. Ferroportin is the sole iron 
export protein in humans and plays a crucial role in main-
taining erythropoiesis, a contributory factor to VO2 max 
[26–28]. Studies in both healthy adults and patients with 
chronic kidney disease have demonstrated that vitamin D 
supplementation significantly decreases systemic hepcidin 
concentrations [24, 25]. Collectively, these findings raise 
the question as to whether optimising total 25(OH)D con-
centrations has a beneficial effect on VO2 max in athletes.
The primary aim of the current study was to test whether 
athletes who received daily vitamin D3 supplementation at 
3000 IU (75 µg) demonstrated a significant increase in VO2 
max compared to those provided with a placebo. Second-
ary aims were to determine whether supplementation influ-
enced skeletal muscle and lung function.
Experimental methods
This 12-week parallel group, double-blind, randomised, 
placebo-controlled trial was conducted at the University of 
Ulster, Coleraine, at a latitude of 55°N between the months 
of November 2014 and April 2015. All procedures were 
approved by the University’s Research Ethics Committee 
(REC/14/0087), and the study was registered at www.clini-
caltrials.gov (NCT02278172) and conducted in accordance 
with the Declaration of Helsinki. The protocol consisted of 
a series of appointments to obtain fasted blood samples and 
other physical measurements before and after a 12-week 
intervention. Nutritional and exercise intervention stud-
ies in athletes and healthy adults have demonstrated that 
12 weeks is a suitable duration to observe a meaningful 
change over time in VO2 max [29–31]. Yet the dose and 
duration of vitamin D supplementation required to have a 
significant impact on VO2 max have not been investigated 
to date.
Subjects
Apparently healthy male and female athletes over the age 
of 18 were considered suitable for inclusion. Exclusion cri-
teria were as follows: not a member of a university sports 
team; vitamin D supplementation and/or iron supplementa-
tion in the 30 days prior to baseline measurements; health 
concern(s)/physical disabilities identified by the screening 
questionnaire that would prevent successful completion of 
the study; consumption of medication(s) known to influ-
ence vitamin D metabolism; vegan athletes; sun-bed users; 
those who had been on a sun holiday in the 30 days prior 
to baseline measurements; those planning a sun holiday 
for during the time frame of the study. Gaelic footballers 
from the university team (n = 72) completed a screening 
questionnaire in the first instance. A total of 42 Gaelic foot-
ballers (n = 18 males and n = 24 females) were deemed 
eligible for inclusion and provided informed consent before 
commencing the study.
Supplements and compliance
An independent clinical trials manager used MINIM 
software [32] to randomise recruited athletes into vita-
min D (VD) or placebo (PL) groups, stratified by sex and 
with an allocation ratio of 1:1. All subjects and research-
ers were blinded to the allocations until completion of the 
study and subsequent data analysis. Footballers allocated 
to the VD group received an oral spray solution provid-
ing 3000 IU(75 µg) vitamin D3 per spray, whereas those 
allocated to the PL group received an oral spray solution 
that did not contain vitamin D but was identical in appear-
ance, smell, taste and from the same brand (BetterYou 
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Ltd, Barnsley, UK). The dose provided was deemed suit-
able to raise total 25(OH)D concentrations to within the 
suggested range for extra-skeletal actions of vitamin D 
(75–100 nmol/L) [33–35]. The vitamin D3 content of sup-
plements was verified by an independent laboratory using 
high-performance liquid chromatography (Eurofins Prod-
uct Testing, Cheshire, UK). Footballers were instructed to 
administer a single spray, targeting the buccal membrane, 
on a daily basis throughout the intervention and to return 
their used spray bottle at their final appointment. Percent-
age compliance was determined by applying the following 
equations.
In Eqs. 1 and 2, D is number of days the spray was taken; 
f refers to the filled weight of the spray bottle, and b is the 
empty spray bottle weight. e is the weight of the spray bot-
tle upon study completion with s referring to the weight of 
each spray. In Eq. 2, C is percentage compliance and d rep-
resents the number of days on intervention. Filled weights 
were based upon the manufacturer’s specifications and the 
average weight of a random sample of 10 oral spray bottles 
from the supplied batch.
Blood collection and processing
Participants were instructed to fast from 10 pm the night 
prior to blood sampling, and regular water intake was 
encouraged. Fasted blood samples were obtained from the 
antecubital fossa using a 21-gauge butterfly needle and 
8 mL serum and 9 mL ethylenediaminetetraacetic acid 
(EDTA) plasma vacutainer tubes (Greiner Bio-One GmbH, 
Kremsmunster, Austria). Following inversion, serum sam-
ples were allowed to clot for <60 min and plasma samples 
placed in refrigeration until centrifugation. Tubes were cen-
trifuged at 2200 rpm for 15 min at 4 °C to allow separation 
of whole blood into its respective components. Following 
separation, serum and plasma samples were pipetted into 
0.5 mL aliquots and stored at −80 °C until further analysis.
Blood analyses
Liquid chromatography-tandem mass spectrometry 
(LCMS-MS) (API 4000; AB SCIEX) was used to quantify 
serum 25(OH)D2 and 25(OH)D3 concentrations, using a 
commercially available assay (Chromsystems Instruments 
and Chemicals GmbH; MassChrom 25-OH-Vitamin D3/
D2). This analysis was undertaken at the Biochemistry 
Department of St James’ Hospital Dublin, a laboratory that 
complies with the Vitamin D External Quality Assessment 
Scheme and use of the National Institute of Standards and 
(1)D = (f− b)− e÷ s.
(2)C = D÷ d× 100.
Technology 972 vitamin D standard reference material. The 
respective inter- and intra-assay coefficients of variation 
were 6.5 and 7.5 %. Plasma intact parathyroid hormone 
concentrations were measured, in duplicate, using a com-
mercially available enzyme-linked immunosorbent assay 
(MD Biosciences Inc., Minnesota, USA). Intra and inter-
assay coefficients of variation were 6.8 and 6.2 %, respec-
tively. Calcium, albumin and creatinine concentrations 
were also measured in duplicate and assessed using an ILab 
650 clinical biochemistry analyser (Instrumentation Labo-
ratory, Massachusetts, USA). Intra-assay coefficients of 
variation were 0.65, 0.85 and 1.65 %, respectively. Intact 
parathyroid hormone and adjusted calcium concentrations 
were measured in order to ensure there were no adverse 
effects of the intervention such as hypoparathyroidism or 
hypercalcaemia [36]. Impaired renal function can lead to 
deleterious effects on vitamin D metabolism, and therefore, 
the renal function of athletes’ was evaluated by estimating 
glomerular filtration rate (eGFR) adjusted for fat-free mass 
[37, 38]. This was quantified from serum creatinine con-
centrations using the Modification of Diet in Renal Disease 
(MDRD) equation [39].
Skeletal muscle function
Average handgrip strength (kg) was measured using a 
dynamometer assembled at handgrip position 2 as default 
with shoulder flexion at 0º and elbow and wrist fully 
extended (Jamar Plus+, Patterson Medical, Warrenville, 
IL, USA) [40]. Footballers held the device alongside their 
body and gripped maximally a total of 3 times. Average 
handgrip strength was calculated for analysis. Vertical jump 
height (cm) was measured using a calibrated electronic 
jump mat (FSL Electronics Ltd, Cookstown, UK). Foot-
ballers performed a counter-movement jump a total of 3 
times, with best recorded jump height used for statistical 
analysis [41]. A standardised rest period of 10 s was given 
between repeats of both handgrip and vertical jump tests.
Lung function
Footballers’ lung function was assessed using a calibrated 
MicroLab portable spirometer (Carefusion Corporation, 
San Diego, CA, USA). Forced vital capacity (FVC) and 
forced expiratory volume at 1 s (FEV1) were quantified by 
exhaling maximally into a 1-way disposable mouthpiece, 
and a minimum of 3 repeats was performed in order to 
derive average values.
Maximal oxygen consumption
Footballers refrained from heavy training/competition for 
at least 24 h prior to exercise testing, in order to control 
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for last-bout effects. Pre- and post-intervention, subjects 
completed an incremental exercise test that was designed 
to elicit a VO2 max response within the capabilities of the 
treadmill (MERC-C, WOODWAY GmbH, Germany). Gas 
analysis was performed using a metabolic cart that has 
been shown to give reliable measurements (Metalyzer 3B, 
CORTEX Biophysik GmbH, Germany) with calibrations 
for ambient conditions, analyser volume and concentrations 
of oxygen and carbon dioxide performed on a daily basis, 
prior to testing [42]. Footballers wore an FT1 heart rate 
monitor (Polar Electro Ltd, Warwick, UK) and face mask 
with triple V insert. Following a standardised warm-up at 
5 km/h (1 % incline), the test began at a running speed of 
8 km/h (1 % incline) and speed increased by 1 km/h every 
minute until a running speed of 17 km/h was attained. At 
this point, running speed remained constant; however, 
incline increased by 1 % each minute until VO2 max was 
achieved. The test was terminated upon volitional exhaus-
tion or if any two of the following criteria were met: respir-
atory exchange ratio >1.15; oxygen plateau observed (i.e. 
no increase in oxygen consumption despite an increase in 
workload); heart rate ±10 bpm of age-predicted maximum 
(208 − 0.7 × age) [43]. Achievement of VO2 max was fur-
ther verified by determining post-exercise lactate concen-
trations, using a Lactate Pro device as per the manufactur-
ers’ recommendations (Arkray Inc, Kyoto, Japan). Peak 
lactate concentrations are reached between 3 and 8 min 
post-exercise [44]; therefore, at 5 min, following cessation 
of the VO2 max test, a 6-µL capillary blood sample was 
obtained for lactate analysis. The lactate response to exer-
cise may also vary according to age and sex. To account 
for this a blood lactate concentration >9 mmol/L in males 
and >7 mmol/L in females was considered as evidence of 
significant anaerobic metabolism [45].
Body composition
Footballers’ height and weight were measured using a sta-
diometer and calibrated scales. Fat mass (FM) and fat-free 
mass (FFM) were measured by whole-body densitometry 
pre- and post-intervention (BOD POD, Life Measurement 
Inc, Concord, CA). The validity of this method has been 
reported extensively elsewhere [46]. Footballers were 
asked to refrain from heavy physical activity for 24 h, and 
testing was performed following an overnight fast. Body 
mass was calculated using a calibrated electronic scale. 
Body volume was determined by air displacement plethys-
mography, corrected for predicted thoracic gas volume. The 
plethysmography chamber was calibrated using a 49.385-L 
cylinder as per manufacturers’ instructions. Percentage 
fat mass (%FM) was calculated using the Siri equation 
[47]. Footballers wore tight-fitting clothing (i.e. swimsuit 
or compression garment with silicone swimming cap), to 
ensure an accurate measurement of body volume, and were 
instructed to sit upright and remain still throughout the test. 
A minimum of two measurements was taken per athlete. 
FM and FFM (kg) were adjusted for athlete’s height (m2) 
and presented as fat mass index (FMI) and fat-free mass 
index (FFMI) (kg/m2) [48].
Dietary assessment
In order to estimate dietary vitamin D intake, footballers 
completed a validated food frequency questionnaire (FFQ) 
[49]. These data were collected on a single occasion due to 
the negligible contribution of dietary sources to total 25(OH)
D concentration and the low intake of such foods in the 
Western diet [50, 51], despite a growing range of vitamin 
D-fortified products. Researchers asked players a series of 
questions relating to their consumption of food items known 
to contain vitamin D, with a photographic food atlas used to 
estimate portion sizes [52].
Physical activity
The validated Recent Physical Activity Questionnaire 
(RPAQ), capable of assessing physical activity for the pre-
vious 4 weeks, was completed pre- and post-intervention to 
control for a change in moderate-vigorous physical activity 
during the study [53]. Participants completed RPAQ ques-
tionnaires during appointments, and the researcher present 
queried any ambiguous responses prior to data entry.
Statistical analysis
An a priori power calculation with a two-sided 5 % sig-
nificance level and power at 95 % determined that 35 ath-
letes were required to observe a statistically significant 
3.5 mL/kg/min increase in VO2 max (G Power version 
3.1) [54]. The final number of recruited athletes (n = 42) 
took into account an estimated dropout rate of 20 %. All 
statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS) with significance 
set at P < 0.05 throughout (IBM SPSS Statistics for Win-
dows, version 21.0, IBM Corp, Armonk, NY). In accord-
ance with the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines, analyses were conducted using 
the intention-to-treat (ITT) principle thereby including all 
athletes randomised at baseline (n = 42) [55]. Missing data 
for physical and biochemical measures were deemed to be 
missing completely at random, owing to injury or illness 
unrelated to the intervention, justifying the use of multiple 
imputation. The Shapiro–Wilk test was used to determine 
whether data followed a normal distribution and skewed 
variables were transformed, using the logarithmic function, 
to attain a normal distribution prior to multiple imputation 
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and further analysis. Transformations were applied to total 
25(OH)D, creatinine and PTH concentrations as well as 
age and change in moderate-vigorous physical activity and 
FFMI. Multiple imputations consisted of 40 imputed data 
sets with pooled data used for subsequent analysis [56]. 
Imputed data are outlined in Fig. 1. Descriptive statistics 
were used to present participant characteristics at baseline. 
An independent t test or a Chi-square test was utilised to 
test for differences between VD and PL groups at baseline. 
ANCOVA models were used to assess the effect of inter-
vention on VO2 max and secondary outcome measures. 
Prognostic covariates were selected a priori for each model 
based upon evidence of a significant interaction between 
the covariate and dependent variable in question [57–60]. 
Reliability of repeated skeletal muscle function tests was 
assessed by pooling pre- and post-intervention data in order 
to determine the standard error of measurement (SEM) 
and intra-class correlation coefficient (ICC) [61]. These 
analyses were performed using the reliability test function 
in SPSS and SEM calculated by applying Cronbach’s α to 




) where SEM is 
standard error of measurement, SD refers to the standard 
deviation of test scores, and rxx refers to Cronbach’s α as 
the reliability measure of test scores [62].
Results
A total of 7 footballers were absent to follow-up (n = 5 VD 
and n = 2 PL) due to sun holidays or illness unrelated to 
the intervention. Use of ITT did not change the outcome of 
the study when compared with per protocol analysis. There 
was no significant difference in the ratio of male to female 
subjects between groups (males n = 12 and females n = 10 
VD; males n = 6 and females n = 14 PL) P = 0.857. The 
participant flow throughout the study is summarised in 
Fig. 1. Footballers’ biochemical and physical characteris-
tics at baseline and week 12 are provided in Table 1. The 
average rate of compliance to the intervention was 95 %. At 
baseline, 50 and 22 % of athletes presented with vitamin D 
insufficiency (31–49 nmol/L) and deficiency (<30 nmol/L), 
respectively. The effect of the intervention on outcome 
measures at week 12, after adjusting for covariates, is 
detailed in Table 2. Supplementation significantly increased 
total 25(OH)D concentrations in the VD group compared 
to PL group, P = 0.006, and resolved vitamin D deficiency 
in all athletes allocated to VD. There was no correlation 
between total 25(OH)D and measures of physical perfor-
mance at either time point, P > 0.05. Furthermore, supple-
mentation with vitamin D3 did not significantly increase 
VO2 max compared to the PL group, P = 0.375. Vitamin 
D3 supplementation did not significantly increase vertical 
jump height when compared to the PL group, P = 0.797, 
and also had no significant effect on left or right handgrip 
strength, P = 0.146 and P = 0.266, respectively. SEM 
and ICC results for vertical jump height (SEM = 1.51, 
r = 0.95), left and right handgrip strength (SEM = 2.06, 
r = 0.96 and SEM = 2.34, r = 0.95, respectively) indicated 
a strong internal consistency across repeated skeletal mus-
cle function tests. Supplementation with vitamin D3 did not 
have a significant effect upon either measure of football-
ers lung function compared to those allocated to PL, FVC 
P = 0.573 and FEV1 P = 0.665. There were no adverse 
health effects to supplementation demonstrated by normal 
adjusted calcium and PTH concentrations at week 12.
Discussion
This is not only the largest investigation of vitamin D sup-
plementation on VO2 max in athletes to date but also the 
first randomised controlled trial to successfully optimise 
vitamin D status using an oral spray solution. In this study, 
over half of the total cohort presented with vitamin D insuf-
ficiency or deficiency at baseline (50 and 22 %, respec-
tively). Such findings corroborate existing literature [3, 5], 
reiterating that athletes are a population that may be at risk 
of poor bone health, owing to total 25(OH)D concentrations 
below 50 nmol/L [63, 64]. Our previous research identified 
this health concern in elite Gaelic footballers, a finding now 
corroborated in those competing at the collegiate level [3]. 
Twelve-week vitamin D3 supplementation using a 3000 IU 
(75 µg) oral spray solution resolved vitamin D deficiency 
and increased mean total serum 25(OH)D concentrations 
to over 80 nmol/L. Conversely, those allocated to the PL 
treatment group remained at potential risk of poor bone 
health with a mean total 25(OH)D concentration below 
50 nmol/L at week twelve [65]. In contrast, Storlie et al. 
[66] reported no significant change in total 25(OH)D con-
centrations over 12 weeks in athletes supplemented daily 
with a 1000 IU (25 µg) vitamin D3 oral spray compared to 
placebo, supporting 3000 IU (75 µg) as an effective win-
tertime dosage. There is ongoing debate over what consti-
tutes an optimal total 25(OH)D concentration for athletes. 
Some speculate that higher total 25(OH)D concentrations 
in excess of 100 nmol/L may be necessary to trigger the 
purported extra-skeletal benefits of vitamin D in athletes 
[67, 68], though there is currently a lack of strong evidence 
for a benefit of maintaining total 25(OH)D concentrations 
above this threshold [35]. Furthermore, toxicity manifests 
itself as hypercalcaemia and increased bone resorption at 
vitamin D supplementation doses exceeding 10,000 IU/day 
(250 µg) or a total 25(OH)D concentration ≈750 nmol/L 
[69]. Indeed, there was a significant change in FMI over 
the 12-week intervention period. FMI increased in the VD 
group but declined in the PL group. Although in-season, 
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this finding may be explained by differences in the foot-
ballers’ individual training and conditioning programmes 
during the winter months in the absence of scheduled train-
ing sessions at the university.
Mechanistic studies support the concept that vitamin 
D may influence VO2 max through direct and indirect 
actions on iron metabolism [24, 25]. Nevertheless, stud-
ies investigating the potential link between total 25(OH)D 
Completed trial per protocol
Bloods (n=17) 
VO2max (n=14)  
Vertical jump (n=15) 
Hand grip (n=17) 
Lung function (n=17)
Athletes’ results subject to intention to 
treat analysis 
Bloods (n=5) 
VO2max (n=8)  
Vertical jump (n=7) 
Hand grip (n=5) 
Lung function (n=5)
Athlete’s included in final analysis (n=22)
Completed trial per protocol
Bloods (n=18) 
VO2max (n=14)  
Vertical jump (n=16) 
Hand grip (n=17) 
Lung function (n=17)
Athletes’ results subject to intention to 
treat analysis 
Bloods (n=2) 
VO2max (n=6)  
Vertical jump (n=4) 
Hand grip (n=3) 
Lung function (n=3)
Athlete’s included in final analysis (n=20)
Allocated to 3000IU cholecalciferol (n=22) 
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Received allocation (n=20) 
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Illness (n=1) 
No longer wished to participate (n=4) 
Follow-up  
Fig. 1  CONSORT flow diagram. A total of 72 Gaelic football-
ers were assessed for eligibility with 30 excluded due to not meet-
ing the inclusion criteria (n = 7) or no longer wishing to participate 
(n = 23). Remaining Gaelic footballers (n = 42) were randomised to 
receive an oral spray solution containing either 3000 IU of vitamin D3 
(n = 22) or placebo (n = 20). A total of 7 athletes were lost to follow-
up owing to illness (n = 1) unrelated to the intervention, sun holi-
day (n = 1) or no longer wishing to participate (n = 5). A total of 35 
athletes completed the study per protocol (vitamin D treatment group 
n = 18 and placebo n = 17). All footballers randomised at baseline 
were included in the final analysis (n = 42)
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Table 1  Footballers’ characteristics at baseline and week 12 expressed as mean ± standard deviation
BMI body mass index, 25(OH)D 25-hydroxyvitamin D, PTH parathyroid hormone, eGFR estimated glomerular filtration rate, VO2 max maximal 
oxygen uptake, FEV1 forced expiratory volume at 1 s, FVC forced vital capacity, FEV1:FVC ratio of forced expiratory volume at 1 s to forced 
vital capacity
a Significant difference between groups at baseline using an independent t test, P < 0.05
b Significant change over time between groups using an ANOVA for normally distributed and transformed data, P < 0.05
Treatment group Vitamin D (n = 22) Placebo (n = 20) P P
Measure Baseline Week 12 Baseline Week 12
Age, year 20 ± 2 – 20 ± 2 – 0.819 –
Height, cm 171.39 ± 8.65 – 165.65 ± 10.18 – 0.048a –
Weight, kg 70.52 ± 11.49 71.1 ± 11.91 61.92 ± 10.69 62.30 ± 10.56 0.009a 0.493
BMI, kg/m2 23.89 ± 2.66 24.30 ± 2.82 22.31 ± 2.19 22.57 ± 2.35 0.031a 0.605
Fat mass index, kg/m2 5.23 ± 2.71 5.70 ± 2.97 5.81 ± 1.94 5.76 ± 2.03 0.439 0.047b
Fat-free mass index, kg/m2 18.95 ± 3.11 18.34 ± 2.51 16.46 ± 1.88 16.89 ± 2.12 0.004a 0.082
Total 25(OH)D, nmol/L 47.37 ± 13.29 83.68 ± 32.98 43.10 ± 22.00 49.22 ± 25.40 0.183 0.001b
25(OH)D2, nmol/L 2.85 ± 1.83 1.91 ± 2.03 2.17 ± 1.96 2.89 ± 1.90 0.313 0.009b
25(OH)D3, nmol/L 44.49 ± 13.35 81.77 ± 33.66 40.93 ± 22.09 46.33 ± 25.64 0.225 0.001b
Vitamin D intake, µg/day 6.73 ± 5.33 – 4.93 ± 2.47 – 0.227 –
PTH, g/dL 41.21 ± 15.98 42.24 ± 20.96 39.28 ± 19.12 43.93 ± 23.65 0.502 0.204
Adjusted calcium, mmol/L 2.29 ± 0.07 2.29 ± 0.09 2.29 ± 0.08 2.31 ± 0.08 0.961 0.427
Creatinine, mmol/L 98.81 ± 11.51 99.21 ± 14.10 89.20 ± 7.10 90.30 ± 9.33 0.001a 0.580
Adjusted eGFR, mL/min/1.73 m3 94.10 ± 9.30 94.92 ± 15.80 98.10 ± 9.76 97.10 ± 11.89 0.439 0.522
Physical activity, h/day 1.06 ± 1.04 0.70 ± 0.59 0.88 ± 0.89 0.51 ± 0.47 0.466 0.749
VO2 max, mL/kg/min 50.46 ± 6.97 50.41 ± 6.96 51.66 ± 6.79 49.33 ± 5.92 0.961 0.176
FEV1, L 3.58 ± 1.03 3.47 ± 0.73 3.13 ± 0.81 3.25 ± 0.86 0.125 0.311
FVC, L 4.20 ± 1.06 3.85 ± 0.92 3.40 ± 0.96 3.58 ± 1.03 0.014a 0.004b
FEV1:FVC, % 86.10 ± 14.44 90.41 ± 6.94 93.02 ± 6.10 92.14 ± 5.41 0.050a 0.115
Vertical jump height, cm 31.71 ± 8.32 32.15 ± 8.91 27.36 ± 6.49 28.85 ± 6.99 0.068 0.619
Left handgrip strength, kg 36.78 ± 10.04 36.77 ± 11.05 29.71 ± 11.56 32.98 ± 11.30 0.039a 0.076
Right handgrip strength, kg 39.29 ± 10.57 39.51 ± 10.76 30.54 ± 11.33 30.07 ± 11.30 0.013a 0.091
Table 2  Effect of intervention 
on outcome measures 
at week 12 expressed as 
mean ± standard deviation
25(OH)D 25-hydroxyvitamin D, VO2 max maximal oxygen uptake, FEV1 forced expiratory volume at 1 s, 
FVC forced vital capacity
a Significant effect of treatment after adjusting for covariates, P < 0.05
b Adjusting for total 25(OH)D concentration pre-intervention
c Adjusting for VO2 max pre-intervention and change in physical activity and FFMI
d Adjusting for FEV1 or FVC pre-intervention, BMI and change in physical activity
e Adjusting for vertical jump height or handgrip strength pre-intervention, change in FFMI, FMI and phys-
ical activity
Treatment group Vitamin D (n = 22) Placebo (n = 20) ANCOVA test statistics
Dependent variable Change from baseline Change from baseline F r2 P
Total 25(OH)D, nmol/L 36.31 ± 32.34 6.11 ± 23.93 15.98 0.396 0.006a, b
VO2 max, mL/kg/min −0.64 ± 1.04 −2.00 ± 0.96 1.12 0.535 0.375c
FEV1, L −0.12 ± 0.73 0.12 ± 0.55 0.36 0.520 0.665d
FVC, L −0.35 ± 0.73 0.18 ± 0.66 1.59 0.569 0.573d
Vertical jump height, cm 0.42 ± 6.59 1.51 ± 6.95 0.09 0.350 0.797e
Left handgrip strength, kg −0.03 ± 5.51 3.30 ± 5.98 2.40 0.665 0.146e
Right handgrip strength, kg 0.18 ± 5.64 3.56 ± 6.69 1.43 0.627 0.266e
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concentration and VO2 max in vivo have yielded equivocal 
findings to date with many failing to account for important 
covariates such as PTH concentrations and participation in 
moderate-vigorous physical activity [13, 15, 70–75]. More-
over, universal criteria for VO2 max have not been firmly 
established and therefore this may contribute to variation 
in study outcomes. Total 25(OH)D concentration was not 
associated with VO2 max at either time point in the cur-
rent study, a finding that is supported by Fitzgerald et al. 
2014 and research conducted in healthy adults [14, 16]. 
In contrast, at a latitude of 35°N, Koundourakis and col-
leagues reported positive bivariate correlations between 
total 25(OH)D concentration and the VO2 max of elite 
footballers, before and after a tapering period spanning 
the months of June and July [17]. During this time, there 
was a small yet significant decrease in athlete’s VO2 max 
despite a concomitant increase in total 25(OH)D concentra-
tions, likely owing to a reduced training load. Such find-
ings indicate that vitamin D does not play a supportive 
role in determining VO2 max in athletes, a concept that is 
substantiated by findings of the current study. Supplemen-
tation did not significantly increase VO2 max compared to 
the PL group despite increasing total 25(OH)D concentra-
tion by 77 %, a finding that has also been shown by others 
[76]. This contrasts with some randomised controlled tri-
als of patients with cardiorespiratory pathology, although 
findings have not been consistent [77, 78]. Established pri-
mary determinants of VO2 max include cardiac output and 
oxygen diffusion capacity [21], and a possible explanation 
for the disparity between athletes and patients may be that 
athletes have a smaller ability to improve VO2 max, owing 
to significant cardiovascular adaptations to aerobic train-
ing including enhanced cardiac output and capillary density 
[79]. It is plausible that such adaptations may outweigh any 
potential benefit of vitamin D supplementation on VO2 max 
when compared to patients with diminished cardiac output 
and/or oxygen diffusion capacity.
The in vitro mechanisms by which vitamin D, specifi-
cally 1,25(OH)2D, may impact upon the skeletal muscle 
function of athletes have been reviewed extensively else-
where, although less is known about the effects of vitamin 
D supplementation on skeletal muscle function in vivo [7, 
80]. Indeed, the effects of vitamin D supplementation on 
skeletal muscle function in athletes have been investigated 
before, albeit without taking into account change in physi-
cal activity or body composition, confounders that deter-
mine skeletal muscle function and may therefore mask a 
null effect of treatment [81, 82]. Total 25(OH)D concen-
tration was not associated with any measure of skeletal 
muscle function in the current study, and supplementation 
did not significantly increase vertical jump height or hand-
grip strength when compared to PL, corroborating find-
ings from a recent randomised controlled trial conducted 
in adolescent swimmers [83]. These results demonstrate 
that vitamin D3 supplementation does not enhance skeletal 
muscle function in younger adults after taking into account 
change in FMI, FFMI and moderate-vigorous physical 
activity, despite increasing total 25(OH)D concentrations to 
over 80 nmol/L. This contrasts with large studies of elderly 
patients that have identified a beneficial effect of vitamin 
D and calcium supplementation on skeletal muscle func-
tion and risk of falls [84–86]. Aside from differences in the 
supplementation regime it is possible to speculate, based 
on the results of the current study and existing literature, 
that vitamin D3 supplementation only benefits skeletal 
muscle in those with diminished function, explaining why 
no ergogenic effect was observed in this cohort of trained 
footballers. Another consideration is that the time taken 
for supplementation to increase total 25(OH)D concentra-
tions to over 50 nmol/L, within the 12-week intervention, 
is not known. Therefore, it is possible that supplementa-
tion only increased total 25(OH)D concentrations to above 
50 nmol/L late in the intervention, leaving little time for a 
measurable effect on skeletal muscle function parameters.
Emerging research also posits that total 25(OH)D con-
centrations may be related to lung function, especially in 
those with airway disease [87–89]. Potential mechanisms 
include enhanced innate immunity and downregulation of 
the T helper 1 cell response, resulting in less airway inflam-
mation and a consequent improvement in overall airway 
function [90]. Nevertheless, this study did not observe an 
association between total 25(OH)D concentration and 
measures of lung function at either time point and, in 
adjusted analyses, supplementation with vitamin D3 did not 
significantly impact upon FEV1 or FVC when compared to 
PL. In unadjusted analyses, there was a significant decrease 
in FVC over time in the VD group compared to those allo-
cated to PL yet this was not the case in adjusted analyses 
indicating that the intervention did not have an adverse 
effect. These findings suggest that the response to vitamin 
D3 supplementation, in terms of benefits on lung function 
parameters, may differ between healthy individuals and 
those with airway disease although larger studies, adjusting 
for lung function specific confounders are required.
To our knowledge this is the first study to investigate 
the effects of vitamin D3 supplementation on VO2 max in 
athletes that has adjusted for key component covariates. 
Strengths of the study include a gender balance of athletes, 
accurate recording of compliance, independently verify-
ing the vitamin D3 content of supplements and being ade-
quately powered to detect any potential significant change 
in VO2 max. Due to the heterogeneous athlete population 
it is not known whether our findings translate to non-Cau-
casian athletes or those from endurance or strength-based 
disciplines. The VO2 max test used in the current study was 
not validated. Future studies in this area are encouraged to 
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utilise a validated protocol. The sample size for this study 
was specific to the primary outcome measure, VO2 max. 
Further research with larger sample sizes may therefore be 
required in order to categorically rule out a beneficial effect 
of vitamin D supplementation on skeletal muscle and lung 
function in athletes. Future studies may also wish to con-
sider stratifying by weight as well as sex to prevent differ-
ences between treatment groups at baseline.
In conclusion, this study observed a high prevalence of 
vitamin D insufficiency and deficiency in collegiate Gaelic 
footballers during wintertime and such individuals should 
consider vitamin D supplementation to avoid being at risk 
of poor bone health. Twelve-week daily supplementation 
with a 3000 IU (75 µg) vitamin D3 oral spray solution is 
an appropriate method, dose and duration to resolve defi-
ciency and increase total 25(OH)D concentrations to over 
80 nmol/L. However, vitamin D supplementation, at the 
dose provided here for 12 weeks, did not have any benefi-
cial effect on VO2 max, skeletal muscle or lung function in 
this cohort of Gaelic footballers.
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